GLP-1 treatment reduces long-term sickness leave, study finds
5 reported
A new working paper from the National Bureau of Economic Research (NBER) estimates the causal impacts of GLP-1 treatment on labor market outcomes. The study uses linked Danish administrative data and a matched stacked difference-in-differences design. Researchers compared patients who initiated GLP-1 treatment during the first two years of Semaglutide availability to observably similar patients who initiated four years later. The analysis found that GLP-1 treatment reduces long-term sickness leave by 17.3%. The study estimates total fiscal benefits of GLP-1 initiation at approximately 1.3–1.5% of annual labor income per employed individual. However, the researchers did not detect statistically significant or economically meaningful impacts on income, labor force participation, or employment over four years.
What’s reported
The study uses linked Danish administrative data and a matched stacked difference-in-differences design.
Researchers compared patients who initiated GLP-1 treatment during the first two years of Semaglutide availability to similar patients who initiated four years later.
GLP-1 treatment reduces long-term sickness leave by 17.3%.
Total fiscal benefits of GLP-1 initiation are estimated at approximately 1.3–1.5% of annual labor income per employed individual.
No statistically significant or economically meaningful impacts were detected on income, labor force participation, or employment over four years.
Sources: marginalrevolution.com
